Boston Scientific Corporation
BSX
Positions held
Your positionsBSX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Boston Scientific is well-positioned in the growing medical devices industry, with a strong focus on innovation and strategic acquisitions to enhance its product portfolio.
- In Q2 2026, revenue increased by 5% compared to the previous quarter, reaching $5.4 billion.
- The operating margin expanded to 22.9% in Q2 2026, indicating improved operational efficiency.
- The stock has a strong sell signal, reflecting bearish market sentiment and potential challenges ahead.
- The company's score is -30.00, indicating significant downward pressure and a trend of 21<50<200.
- The net income for Q2 2026 was $907 million, down from $1.34 billion in Q1 2026, highlighting a concerning decline in profitability.
Fundamentals
| Market cap | $60.93B | Enterprise value | $73.25B | Trailing P/E | 17.02 | Forward P/E | 12.43 |
| PEG | 0.58 | Price / book | 2.44 | Beta | 0.58 | Dividend yield | 0.00% |
| Revenue growth | 7.5% | Earnings growth | 15.1% | Gross margin | 69.2% | Operating margin | 22.9% |
| Profit margin | 17.5% | ROE | 15.3% | ROA | 6.2% | Debt / equity | 0.50 |
| Current ratio | 1.24 | Free cash flow | $2.45B | Analyst recommendation | buy | Mean target | $59.90 |
| 52w high | $105.65 | 52w low | $41.39 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $5.4B | $5.2B | $5.3B | $5.1B | $5.1B |
| Op margin | 22.9% | 20.6% | 19.7% | 20.7% | 18.6% |
| Net income | $907M | $1.3B | $672M | $755M | $797M |
| Gross margin | 70.7% | 69.4% | 69.6% | 69.9% | 67.7% |
| Gross profit | $3.8B | $3.6B | $3.7B | $3.5B | $3.4B |
| Operating income | $1.2B | $1.1B | $1.0B | $1.1B | $943M |
- Revenue +5% vs prior quarter ($5.4B vs $5.2B).
- Gross margin 70.7% (was 69.4% prior quarter).
- Operating margin expanded to 22.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $20.1B | $16.7B | $14.2B | $12.7B | — |
| Op margin | 19.8% | 17.9% | 17.0% | 16.0% | — |
| Net income | $2.9B | $1.9B | $1.6B | $698M | — |
| Gross margin | 69.0% | 68.6% | 69.5% | 68.8% | — |
| Gross profit | $13.9B | $11.5B | $9.9B | $8.7B | — |
| Operating income | $4.0B | $3.0B | $2.4B | $2.0B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Boston sues J&J subsidiary over alleged patent infringement for cardiology device
2026-10-09 · Leerink Partners Adjusts Price Target on Boston Scientific to $55 From $60
2026-10-08 · Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors
2026-10-08 · Boston Scientific Corporation (BSX) is Attracting Investor Attention: Here is What You Should Know
2026-10-08 · Boston Scientific names Joseph Fitzgerald as chief operating officer
2026-10-08 · 1 Safe-and-Steady Stock to Research Further and 2 Facing Challenges
2026-10-08 · Why Is Boston Scientific (BSX) Reorganizing Into Three Segments Under A New COO?
2026-10-07 · Evercore ISI Adjusts Price Target on Boston Scientific to $52 From $65
2026-10-07 · Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
2026-10-07 · Boston Scientific Names Joseph Fitzgerald as COO
2026-10-07 · Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
2026-10-07 · Stryker (SYK) vs Boston Scientific (BSX): Which is a Better Stock to Buy?
Price (daily)
Full chart · RSI · MACD · patterns